FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304698082> ?p ?o ?g. }

• W4304698082 endingPage "404" @default.
• W4304698082 startingPage "393" @default.
• W4304698082 abstract "Nearly half of advanced melanoma patients do not achieve a clinical response with anti-programmed cell death 1 protein (PD1) therapy (i.e. primary resistance) or initially achieve a clinical response but eventually progress during or following further treatment (i.e. secondary resistance). A consensus definition for tumor resistance to anti-PD1 monotherapy was published by Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce (SITC) in 2020. A systematic literature review (SLR) of clinical trials and observational studies was conducted to characterize the proportions of advanced melanoma patients who have progressed on anti-PD1 therapies. The SLR included 55 unique studies and the SITC definition of primary resistance was applied to 37 studies that specified disease progression by best overall response. Median and range of patients with primary resistance in studies that specified first-line and second-line or higher anti-PD1 monotherapy was 35.50% (21.19-39.13%; n = 4 studies) and 41.54% (30.00-56.41%, n = 3 studies); median and range of patients with primary resistance in studies that specified first-line and second-line or higher combination therapy was 30.23% (15.79-33.33%; n = 6 studies), and 70.00% (61.10-73.33%; n = 3 studies). Primary resistance to anti-PD1 monotherapies and when in combination with ipilimumab are higher in patients receiving second-line or higher therapies, in patients with acral, mucosal, and uveal melanoma, and in patients with active brain metastases. The percentage of patients with primary resistance was generally consistent across clinical trials, with variability in resistance noted for observational studies. Limitations include applying the SITC definitions to combination therapies, where consensus definitions are not yet available. Future studies should highly consider utilizing the SITC definitions to harmonize how resistance is classified and facilitate meaningful context for clinical activity." @default.
• W4304698082 created "2022-10-12" @default.
• W4304698082 creator A5000768609 @default.
• W4304698082 creator A5016971711 @default.
• W4304698082 creator A5054425112 @default.
• W4304698082 creator A5061816287 @default.
• W4304698082 creator A5070490849 @default.
• W4304698082 creator A5077461078 @default.
• W4304698082 creator A5091485339 @default.
• W4304698082 date "2022-10-07" @default.
• W4304698082 modified "2023-10-01" @default.
• W4304698082 title "Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions" @default.
• W4304698082 cites W2098923148 @default.
• W4304698082 cites W2166662937 @default.
• W4304698082 cites W2338494814 @default.
• W4304698082 cites W2412250098 @default.
• W4304698082 cites W2519279652 @default.
• W4304698082 cites W2519469881 @default.
• W4304698082 cites W2572843558 @default.
• W4304698082 cites W2586803984 @default.
• W4304698082 cites W2591306501 @default.
• W4304698082 cites W2607506177 @default.
• W4304698082 cites W2650204451 @default.
• W4304698082 cites W2726861941 @default.
• W4304698082 cites W2735117693 @default.
• W4304698082 cites W2747107882 @default.
• W4304698082 cites W2763456084 @default.
• W4304698082 cites W2765564427 @default.
• W4304698082 cites W2782007611 @default.
• W4304698082 cites W2794627893 @default.
• W4304698082 cites W2800500049 @default.
• W4304698082 cites W2888298425 @default.
• W4304698082 cites W2898510820 @default.
• W4304698082 cites W2898547742 @default.
• W4304698082 cites W2912991678 @default.
• W4304698082 cites W2913383852 @default.
• W4304698082 cites W2915708315 @default.
• W4304698082 cites W2933124473 @default.
• W4304698082 cites W2938667209 @default.
• W4304698082 cites W2947765148 @default.
• W4304698082 cites W2947771252 @default.
• W4304698082 cites W2951285627 @default.
• W4304698082 cites W2951610783 @default.
• W4304698082 cites W2963476376 @default.
• W4304698082 cites W2963686803 @default.
• W4304698082 cites W2968119443 @default.
• W4304698082 cites W2969246868 @default.
• W4304698082 cites W2970435082 @default.
• W4304698082 cites W2972182678 @default.
• W4304698082 cites W2978943095 @default.
• W4304698082 cites W2984462607 @default.
• W4304698082 cites W2985211404 @default.
• W4304698082 cites W3001076836 @default.
• W4304698082 cites W3010989413 @default.
• W4304698082 cites W3011243232 @default.
• W4304698082 cites W3014748351 @default.
• W4304698082 cites W3023280404 @default.
• W4304698082 cites W3032907163 @default.
• W4304698082 cites W3033948992 @default.
• W4304698082 cites W3038039573 @default.
• W4304698082 cites W3039168692 @default.
• W4304698082 cites W3042416076 @default.
• W4304698082 cites W3043703771 @default.
• W4304698082 cites W3045615435 @default.
• W4304698082 cites W3083337362 @default.
• W4304698082 cites W3155601180 @default.
• W4304698082 cites W3171006409 @default.
• W4304698082 cites W3176956457 @default.
• W4304698082 cites W3196898938 @default.
• W4304698082 cites W4211223138 @default.
• W4304698082 cites W4294215472 @default.
• W4304698082 doi "https://doi.org/10.1097/cmr.0000000000000850" @default.
• W4304698082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36223314" @default.
• W4304698082 hasPublicationYear "2022" @default.
• W4304698082 type Work @default.
• W4304698082 citedByCount "3" @default.
• W4304698082 countsByYear W43046980822023 @default.
• W4304698082 crossrefType "journal-article" @default.
• W4304698082 hasAuthorship W4304698082A5000768609 @default.
• W4304698082 hasAuthorship W4304698082A5016971711 @default.
• W4304698082 hasAuthorship W4304698082A5054425112 @default.
• W4304698082 hasAuthorship W4304698082A5061816287 @default.
• W4304698082 hasAuthorship W4304698082A5070490849 @default.
• W4304698082 hasAuthorship W4304698082A5077461078 @default.
• W4304698082 hasAuthorship W4304698082A5091485339 @default.
• W4304698082 hasConcept C121608353 @default.
• W4304698082 hasConcept C126322002 @default.
• W4304698082 hasConcept C143998085 @default.
• W4304698082 hasConcept C2777658100 @default.
• W4304698082 hasConcept C2777701055 @default.
• W4304698082 hasConcept C2780030458 @default.
• W4304698082 hasConcept C2781433595 @default.
• W4304698082 hasConcept C2994294914 @default.
• W4304698082 hasConcept C502942594 @default.
• W4304698082 hasConcept C535046627 @default.
• W4304698082 hasConcept C71924100 @default.
• W4304698082 hasConceptScore W4304698082C121608353 @default.
• W4304698082 hasConceptScore W4304698082C126322002 @default.

• next